Analytical Data
-
Gene name
IL-17RA
- Application
-
Alternative Names
CDw217; CD217; IL17R-A; IL17-RA; IL17R-A; IL17R; HIL-17R
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
D4A740
-
Expression Region
Gly617~Gly847
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-17 receptor A (IL-17RA) is a crucial component of the IL-17 signaling pathway, which plays a significant role in the immune response, particularly in inflammation and autoimmune diseases. The IL-17 family of cytokines, which includes IL-17A, IL-17F, and others, binds to IL-17RA and its partner receptors to activate downstream signaling pathways that lead to the production of pro-inflammatory cytokines and chemokines. Dysregulation of this pathway has been implicated in various conditions, such as rheumatoid arthritis, psoriasis, and multiple sclerosis. Consequently, IL-17RA has become an attractive target for therapeutic intervention. Researchers have been focusing on the development of recombinant IL-17RA proteins, which can serve both as potential therapeutics and as research tools to better understand IL-17 signaling. These recombinant proteins can act as competitive antagonists, inhibiting IL-17 signaling by binding to IL-17A and preventing its interaction with the receptor complex, thereby mitigating the inflammatory response. Furthermore, these studies aim to delineate the precise role of IL-17RA in various disease contexts, providing insights into how IL-17-mediated pathways can be modulated for therapeutic benefit. The development of IL-17RA recombinant proteins, therefore, represents a critical area of research with the potential for advancing the treatment of autoimmune diseases by targeting the underlying inflammatory mechanisms.
